Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
← catalyst calendarNCT07691970 · readout in 2,326 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
1,072estimated
Sites
41
Countries
Austria, Belgium, Brazil +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-01 | estimated | When the study began enrolling |
| Primary completion | 2032-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Interventions
- Combination product: Anifrolumab
- Combination product: Anifrolumab
- Drug: Anifrolumab
Primary outcome
what the primary-completion date above is the date OFSAEs and Non-Serious AEs
measured From first dose administered and until 12 weeks after the last dose of Anifrolumab
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed